Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[ b ]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties

Journal of Medicinal Chemistry

Volumn 54, Issue 17, 2011, Pages 6014-6027

  Flynn, Bernard L ^a,b   Gill, Gurmit S ^a   Grobelny, Damian W ^a   Chaplin, Jason H ^a   Paul, Dharam ^a   Leske, Annabell F ^a   Lavranos, Tina C ^a   Chalmers, David K ^b   Charman, Susan A ^b   Kostewicz, Edmund ^b   Shackleford, David M ^b   Morizzi, Julia ^b   Hamel, Ernest ^c   Jung, M Katherine ^d   Kremmidiotis, Gabriel ^a  

^a Bionomics Ltd   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXY 6 METHOXY 2 METHYL 3 (3,4,5 TRIMETHOXYBENZOYL)BENZO[B]FURAN; ANTINEOPLASTIC AGENT; BENZOFURAN DERIVATIVE; BNC 105; COMBRETASTATIN A4 PHOSPHATE; DISODIUM HYDROGEN PHOSPHATE; PRODRUG; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL ACTIVATION; CONTROLLED STUDY; DRUG CONFORMATION; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VIVO STUDY; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

ANISOLES; AORTA; BENZOFURANS; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN MODULATORS;

EID: 80052351229     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200454y     Document Type: Article

References (85)

1. Jordan, M. A.; Wilson, L. Microtubules as a target for anticancer drugs Nat. Rev. Cancer 2004, 4, 253-265 (Pubitemid 38525281)
2. Lopus, M.; Yenjerle, M.; Wilson, L. Microtubule Dynamics. In Wiley Encyclopedia of Chemical Biology; Begley, T. P., et al.; Eds.; John Wiley and Sons, Inc.: Hoboken, NJ, 2008; 3, 153-160.
3. Etienne-Manneville, S. From signaling pathways to microtubule dynamics: the key players Curr. Opin. Cell Biol. 2010, 22, 104-111
4. Wade, R. H. On and around microtubules: an overview Mol. Biotechnol. 2009, 43, 177-191
5. Kavallaris, M.; Verrills, N. M.; Hill, B. T. Anticancer therapy with novel tubulin-interacting drugs Drug Resist. Updates 2001, 4, 392-401 (Pubitemid 34746873)
6. Hearn, B. R.; Shaw, S. J.; Myles, D. C. Microtubule Targeting Agents, Compr. Med. Chem. II 2006, 7, 81-110
7. Bedard, P. L.; Di Leo, A.; Piccart-Gebhart, M. J. Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer Nat. Rev. Clin. Oncol 2010, 7, 22-36
8. Hadfield, J. A.; Ducki, S.; Hirst, N.; McGown, A. T. Tubulin and microtubules as targets for anticancer drugs Prog. Cell Cycle Res. 2003, 5, 309-325
9. Chen, J.; Liu., T.; Dong, X.; Hu, Y. Recent developments and SAR analysis of colchicine binding site inhibitors Mini-Rev. Med. Chem. 2009, 9, 1174-1190
10. Chaudhary, A.; Pandeya, S. N.; Kumar, P.; Sharma, P. P.; Gupta, S.; Soni, N.; Verma, K. K.; Bhardwaj, G. Combretastatin A-4 analogs as anticancer agents Mini-Rev. Med. Chem. 2007, 7, 1186-1205 (Pubitemid 350303084)
11. Tron, G. C.; Pirali, T.; Sorba, G.; Pagliai, F.; Busacca, S.; Genazzani, A. A. Medicinal chemistry of combretastatin A4: present and future directions J. Med. Chem. 2006, 49, 3033-3044 (Pubitemid 43830499)
12. Pinney, K. G.; Jelinek, C.; Edvardsen, K.; Chaplin, D. J.; Pettit, G. R. The Discovery and Development of the Combretastatins. In Anticancer Agents from Natural Products; Cragg, G. M.; Kingston, D. G. I.; Newman, D. J., Eds; Taylor and Francis: Boca Raton, FL, 2005; pp 23-46.
13. Bhattacharyya, B.; Panda, D.; Gupta, S.; Banerjee, M. Antimitotic activity of colchicine and the structural basis for its interaction with tubulin Med. Res. Rev. 2008, 28, 155-183 (Pubitemid 350274963)
14. Hamel, E. An Overview of Compounds That Interact with Tubulin and Their Effects on Microtubule Assembly. In The Role of Microtubules in Cell Biology, Neurobiology and Oncology; Fojo, T., Ed.; Humana Press: Totowa, NJ, 2008; pp 1-19.
15. Romagnoli, R.; Baraldi, P. G.; Carrion, M. D.; Cruz-Lopez, O.; Tolomeo, M.; Grimaudo, S.; Di Cristina, A.; Pipitone, M. R.; Balzarini, J.; Brancale, A.; Hamel, E. Substituted 2-(3′,4′,5′-trimethoxybenzoyl)-benzo[ b ]thiophene derivatives as potent tubulin polymerization inhibitors Bioorg. Med. Chem. 2010, 18, 5114-5122
16. Chen, J.; Wang, Z.; Lu, Y.; Dalton, J. T.; Miller, D. D.; Li, W. Synthesis and antiproliferative activity of imidazole and imidazoline analogs for melanoma Bioorg. Med. Chem. Lett. 2008, 18, 3183-3187 (Pubitemid 351718344)
17. Lu, Y.; Li, C. M.; Wang, Z.; Ross, C. R., II; Chen, J.; Dalton, J. T.; Li, W.; Miller, D. D. Discovery of 4-substituted methoxybenzoyl-aryl-thiazoles as novel anticancer agents: synthesis, biological evaluation, and structure-activity relationships J. Med. Chem. 2009, 52, 1701-1711
18. La Regina, G.; Sarkar, T.; Bai, R.; Edler, M. C.; Saletti, R.; Coluccia, A.; Piscitelli, F.; Minelli, L.; Gatti, V.; Mazzoccoli, C.; Palermo, V.; Mazzoni, C.; Falcone, C.; Scovassi, A. I.; Giansanti, V.; Campiglia, P.; Porta, A.; Maresca, B.; Hamel, E.; Brancale, A.; Novellino, E.; Silvestri, R. New arylthioindoles and related bioisosteres at the sulfur bridging group. 4. Synthesis, tubulin polymerization, cell growth inhibition, and molecular modeling studies J. Med. Chem. 2009, 52, 7512-7527
19. Gangjee, A.; Zhao, T.; Lin, L.; Raghavan, S.; Roberts, E. G.; Risinger, A. L.; Hamel, E.; Mooberry, S. L. Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance J. Med. Chem. 2010, 53, 8116-8128
20. Schobert, R.; Biersack, B.; Dietrich, A.; Effenberger, K.; Knauer, S.; Mueller, T. 4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and-N -methylimidazoles that are cytotoxic against combretastatin A-4 resistant tumor cells and vascular disrupting in a cisplatin resistant germ cell tumor model J. Med. Chem. 2010, 53, 6595-6602
21. Lee, J.; Kim, S. J.; Choi, H.; Kim, Y. H.; Lim, I. T.; Yang, H.-M.; Lee, C. S.; Kang, H. R.; Ahn, S. K.; Moon, S. K.; Kim, D.-H.; Lee, S.; Choi, N. M.; Lee, K. J. Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors J. Med. Chem. 2010, 53, 6337-6354
22. Romagnoli, R.; Baraldi, P. G.; Cruz-Lopez, O.; Cara, C. L.; Carrion, M. D.; Brancale, A.; Hamel, E.; Chen, L.; Bortolozzi, R.; Basso, G.; Viola, G. Synthesis and antitumor activity of 1,5-disubstituted 1,2,4-triazoles as cis-restricted combretastatin analogues J. Med. Chem. 2010, 53, 4248-4258
23. Jourdan, F.; Leese, M. P.; Dohle, W.; Hamel, E.; Ferrandis, E.; Newman, S. P.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-methoxyestradiol-3,17- O, O -bis-sulfamate J. Med. Chem. 2010, 53, 2942-2951
24. Lee, L.; Robb, L. M.; Lee, M.; Davis, R.; Mackay, H.; Chavda, S.; Babu, B.; L.; O'Brien, E.; Risinger, A. L.; Mooberry, S. L.; Lee, M. Design, synthesis, and biological evaluations of 2,5-diaryl-2,3-dihydro-1,3,4- oxadiazoline analogs of combretastatin-A4 J. Med. Chem. 2010, 53, 325-334
25. Bonezzi, K.; Taraboletti, G.; Borsotti, P.; Bellina, F.; Rossi, R.; Giavazz, R. Vascular disrupting activity of tubulin-binding 1,5-diaryl-1 H -imidazoles J. Med. Chem. 2009, 52, 7906-7910
26. Wu, Y.-S.; Coumar, M. S.; Chang, J.-Y.; Sun, H.-Y.; Kuo, F.-M.; Kuo, C.-C.; C., Y.-J.; Chang, C.-Y.; Hsiao, C.-L.; Liou, J.-P.; Chen, C.-P.; Yao, H.-T.; Chiang, Y.-K.; Tan, U.-K.; Chen, C.-T.; Chu, C.-Y.; Wu, S.-Y.; Yeh, T.-K.; Lin, C.-Y.; Hsieh, H.-P. Synthesis and evaluation of 3-aroylindoles as anticancer agents: metabolite approach J. Med. Chem. 2009, 52, 4941-4945
27. Ty, N.; Dupeyre, G.; Chabot, G. G.; Seguin, J.; Tillequin, F.; Scherman, D.; Michel, S.; Cahcet, X. Bioorg. Med. Chem. 2008, 16, 7494-7503
28. Chiang, Y.-K.; Kuo, C.-C.; Wu, Y.-S.; Chen, C.-T.; Coumar, M. S.; Wu, J.-S.; Hsieh, H.-P.; Chang, C.-Y.; Jseng, H.-Y.; Wu, M.-H.; Leou, J.-S.; Song, J.-S.; Chang, J.-Y.; Lyu, P.-C.; Chao, Y.-S.; Wu, S.-Y. Generation of ligand-based pharmacophore model and virtual screening for identification of novel tubulin inhibitors with potent anticancer activity J. Med. Chem. 2009, 52, 4221-4233
29. Max, M. A. Small-molecule, tubulin-binding compounds as vascular targeting agents Expert Opin. Ther. Pat. 2002, 12, 769-776
30. Tozer, G. M.; Kanthou, C.; Baguley, B. C. Disrupting tumour blood vessels Nat. Rev. Cancer 2005, 5, 423-435 (Pubitemid 40791485)
31. Siemann, D. W.; Chaplin, D. J.; Horsman, M. R. Vascular targeted therapies for treatment of malignant disease Cancer 2004, 100, 2491-2499 (Pubitemid 38715753)
32. Kanthou, C.; Tozer, G. M. The tumor vascular targeting agent combretastatin A-4 phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells Blood 2002, 99, 2060-2069 (Pubitemid 34525489)
33. Young, S. L.; Chaplin, D. J. Combretastatin A4 phosphate: background and current clinical status Expert Opin. Invest. Drugs 2004, 13, 1171-1182 (Pubitemid 39242740)
34. Nagaiah, G.; Remick, S. C. Combretastatin A4 phosphate: a novel vascular disrupting agent Future Oncol. 2010, 6, 1219-1228
35. McKeage, M. J.; Baguley, B. C. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer Cancer 2010, 116, 1859-1871
36. Kanthou, C.; Tozer, G. M. Tumour targeting by microtubule-depolymerising vascular disrupting agents Expert Opin. Ther. Targets 2007, 11, 1443-1457 (Pubitemid 350200480)
37. Schwartz, E. L. Antivascular actions of microtubule-binding drugs Clin. Cancer Res. 2009, 15, 2595-2601
38. Chaplin, D. J.; Dougherty, G. J.; Siemann, D. W. Vascular disrupting agents Antiangiogenic Cancer Ther. 2008, 329-364
39. Siemann, D. W.; Chaplin, D. J.; Walicke, P. A. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P) Expert Opin. Invest. Drugs 2009, 18, 189-197
40. Vascular-Targeted Therapies in Oncology; Siemann, D. W., Ed.; John Wiley and Sons: New York, 2006.
41. Patnaik, P. A Comprehensive Guide to the Hazadous Properties of Chemical Substances; John Wiley & Sons: Hoboken, NJ, 2007; p 229.
42. IPCS INCHEM. Colchicine. http://www.inchem.org/documents/pims/pharm/ colchic.htm.
43. Kang, G.-J.; Getahun, Z.; Muzaffar, A.; Brossi, A.; Hamel, E. N -Acetylcolchicinol O -methyl ether and thiocolchicine, potent analogs of colchicine modified in the C ring J. Biol. Chem. 1990, 256, 10255-10259
44. Niel, E.; Scherrmann, J.-M. Colchicine today Jt., Bone, Spine 2006, 73, 672-678 (Pubitemid 44932240)
45. Blakey, D. C.; Ashton, S. E.; Westwood, F. R.; Walker, M.; Anderson, J. R. ZD6126: a novel small molecule vascular targeting agent Int. J. Radiat. Oncol., Biol., Phys. 2002, 54, 1497-1502 (Pubitemid 35380055)
46. Davis, P. D.; Dougherty, G. J.; Blakey, D. C.; Galbraith, S. M.; Tozer, G. M.; Holder, A. L.; Naylor, M. A.; Nolan, J.; Stratford, M. R. L.; Chaplin, D. J.; Hill, S. A. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature Cancer Res. 2002, 62, 7247-7253 (Pubitemid 36025246)
47. LoRusso, P. M.; Gadgeel, S. M.; Wozniak, A.; Barge, A. J.; Jones, H. K.; DelProposto, Z. S.; DeLuca, P. A.; Evelhoch, J. L.; Boerner, S. A.; Wheeler, C. Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors Invest. New Drugs 2008, 26, 159-167
48. Beerepoot, L. V.; Radema, S. A.; Witteveen, E. O.; Thomas, T.; Wheeler, C.; Kempin, S.; Voest, E. E. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors J. Clin. Onocol. 2006, 24, 1492-1498
49. Rustin, G. J.; Shreeves, G.; Nathan, P. D.; Gaya, A.; Ganesan, T. S.; Wang, D.; Boxall, J.; Poupard, L.; Chaplin, D. J.; Stratford, M. R. L.; Balkissoon, J.; Zweifel, M. A phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer Br. J. Cancer 2010, 102, 1355-1360 and references therein
50. Lickliter, J. D.; Francesconi, A. B.; Smith, G.; Burge, M.; Coulthard, A.; Rose, S.; Griffin, M.; Milne, R.; McCarron, J.; Yeadon, T.; Wilks, A.; Cubitt, A.; Wyld, D. K.; Vasey, P. A. Phase I trial of CYT997, a novel cytotoxic and vascular disrupting agent Br. J. Cancer 2010, 103, 597-606
51. Mita, M. M.; Spear, M. A.; Yee, L. K.; Mita, A. C.; Heath, E. I.; Papadopoulos, K. P.; Federico, K. C.; Reich, S. D.; Romero, O.; Malburg, L.; Pilat, M.-J.; Lloyd, G. K.; Neuteboom, S. T. C.; Cropp, G.; Ashton, E.; LoRusso, P. M. Phase 1 first-in-human trial of the vascular disrupting agent plinabulin (NPI-2358) in patients with solid tumors or lymphomas Clin. Cancer Res. 2010, 16, 5892-5899
52. Baguley, B. C.; McKeage, M. J. ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy Future Oncol. 2010, 6, 1537-1543
53. Hinnen, P.; Eskens, F. A. L. M. Vascular disrupting agents in clinical development Br. J. Cancer 2007, 96, 1159-1165 (Pubitemid 46625071)
54. Lippert, J. W. Vascular disrupting agents Bioorg. Med. Chem. 2007, 15, 605-615
55. Rojiani, M. V.; Rojiani, A. M. Morphologic Manifestations of Vascular-Disrupting Agents in Preclinical Models. In Vascular-Targeted Therapies in Oncology; Siemann, D. W., Ed.; John Wiley and Sons: New York, 2006; pp 81-94.
56. Shi, W.; Horsman, M. R.; Siemann, D. W. Combined Modality Approaches Using Vasculature-Disrupting Agents. In Vascular-Targeted Therapies in Oncology; Siemann, D. W., Ed.; John Wiley and Sons: New York, 2006; pp 123-136.
57. Hua, J.; Sheng, Y.; Pinney, K. G.; Garner, C. M.; Kane, R. R.; Prezioso, J. A.; Pettit, G. R.; Chaplin, D. J.; Edvardsen, K. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate Anticancer Res. 2003, 23, 1433-1440 (Pubitemid 36754111)
58. Kremmidiotis, G.; Leske, A. F.; Lavranos, T. C.; Beaumont, D.; Gasic, J.; Hall, A.; O'Callaghan, M.; Matthews, C. A.; Flynn, B. L. BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy Mol. Cancer Ther. 2010, 9, 1562-1573
59. Chaplin, J. H.; Gill, G. S.; Grobelny, D. W.; Flynn, B. L. Preparation of Benzofurans and Related Derivatives as Tubulin Polymerization Inhibitors for Treating Neoplasm and Inflammation. PCT Int. Appl. WO2006084338, 2006.
60. Chaplin, J. H.; Gill, G. S.; Grobelny, D. W.; Flynn, B. L.; Kremmidiotis, G. Substituted Benzofurans, Benzothiophenes, Benzoselenophenes and Indoles and Their Use as Tubulin Polymerization Inhibitors. PCT Int. Appl. WO2007087684, 2007.
61. Pinney, K. G.; Bounds, A. D.; Dingeman, K. M.; Mocharla, V. P.; Pettit, G. R.; Bai, R.; Hamel, E. A new anti-tubulin agent containing the benzo[ b ]thiophene ring system Bioorg. Med. Chem. Lett. 1999, 9, 1081-1086 (Pubitemid 29204661)
62. Mullica, D. F.; Pinney, K. G.; Mocharla, V. P.; Dingeman, K. M.; Bounds, A. D.; Sappenfield, E. L. Characterization and structural analyses of trimethoxy and triethoxybenzo[ b ]thiophene J. Chem. Crystallogr. 1998, 28, 289-295 (Pubitemid 128364746)
63. Flynn, B. L.; Verdier-Pinard, P.; Hamel, E. A novel palladium-mediated coupling approach to 2,3-disubstituted benzo[ b ]thiophenes and its application to the synthesis of tubulin binding agents Org. Lett. 2001, 3, 651-654
64. Flynn, B. L.; Flynn, G. P.; Hamel, E.; Jung, M. K. The synthesis and tubulin binding activity of thiophene-based analogues of combretastatin A-4 Bioorg. Med. Chem. Lett. 2001, 11, 2341-2343 (Pubitemid 32781695)
65. Flynn, B. L.; Hamel, E.; Jung, M. K. A one-pot synthesis of benzo[ b ]furan and indole inhibitors of tubulin polymerization J. Med. Chem. 2002, 45, 2670-2673 (Pubitemid 34595238)
66. Related indenones I (X = carbonyl) are inactive: Kerr, D. J.; Hamel, E.; Jung, M. K.; Flynn, B. L. The concise synthesis of chalcone, indanone and indenone analogues of combretastatin A4 Bioorg. Med. Chem. 2007, 15, 3290-3298 (Pubitemid 46505268)
67. Liou, J.-P.; Chang, Y.-C.; Kuo, F.-M.; Chang, C-.W.; Tseng, H.-Y.; Wang, C.-C.; Yang, Y.-N.; Chang, J.-Y.; Lee, S.-J.; Hsieh, H. P. Concise synthesis and structure-activity relationships of combretastatins A-4 analogues, 1-aroylindoles and 3-aroylindoles, a novel class of potent antitubulin agents J. Med. Chem. 2004, 47, 4247-4257 (Pubitemid 39045430)
68. Chaplin, J. H.; Flynn, B. L. A multi-component coupling approach to benzo[ b ]furans and indoles J. Chem. Soc., Chem. Commun. 2001, 1594-1595 (Pubitemid 32808010)
69. Gill, G. S.; Grobelny, D. W.; Chaplin, J. H.; Flynn, B. L. An efficient synthesis and substitution of 3-aroyl-2-bromobenzo[ b ]furans J. Org. Chem. 2008, 73, 1131-1134 (Pubitemid 351198764)
70. Larock, R. C.; Yum, E. K.; Doty, M. J.; Sham, K. C. Synthesis of aromatic heterocycles via palladium-catalyzed annulation of internal alkynes J. Org. Chem. 1995, 60, 3270-3271
71. Bussolati, B.; Deambrosis, I.; Russo, S.; Deregibus, M. C.; Camussi, G. Altered angiogenesis and survival in human tumor-derived endothelial cells FASEB J. 2003, 17, 1159-1161
72. Ohsumi, K.; Nakagawa, R.; Fukuda, Y.; Hatanaka, T.; Morinaga, Y.; Nihei, Y.; Ohishi, K.; Suga, Y.; Akiyama, Y.; Tsuji, T. Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships J. Med. Chem. 1998, 41, 3022-3032 (Pubitemid 28359938)
73. Maya, A. B. S.; Perez-Melero, C.; Mateo, C.; Alonso, D.; Fernandez, J. L.; Gajate, C.; Mollinedo, F.; Pelaez, R.; Caballero, E.; Medarde, M. Further naphthylcombretastatins. An investigation on the role of the naphthalene moiety J. Med. Chem. 2005, 48, 556-568 (Pubitemid 40139798)
74. Cushman, M.; Nagarathnam, D.; Gopal, D.; Chakraborti, A. K.; Lin, C. M.; Hamel, E. Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization J. Med. Chem. 1991, 34, 2579-2588
75. Ravelli, R. B. G.; Gigant, G.; Curmi, P. A.; Jourdain, I.; Lachkar, S.; Sobel, A.; Knossow, M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain Nature 2004, 428, 198-202 (Pubitemid 38374318)
76. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes J. Med. Chem. 2006, 49, 6177-6196 (Pubitemid 44595196)
77. For other docking studies on tubulin see the following: Soulère, L. Toward docking-based virtual screening for discovering antitubulin agents by targeting taxane and colchicines binding sites ChemMedChem 2009, 4, 161-163 and references cited therein
78. Goda, K.; Bacso, Z.; Szabo, G. Multidrug resistance through the spectacle of P-glycoprotein Curr. Cancer Drug Targets 2009, 9, 281-297
79. Battaglia, A.; Bernacki, R. J.; Bertucci, C.; Bombardelli, E.; Cimitan, S.; Ferlini, C.; Fontana, G.; Guerrini, A.; Riva, A. Synthesis and biological evaluation of 2′-methyl taxoids derived from baccatin III and 14β-OH-baccatin III 1,14-carbonate J. Med. Chem. 2003, 46, 4822-4825 (Pubitemid 37352020)
80. Martirosyan, A.; Clendening, J. W.; Goard, C. A.; Penn, L. Z. Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance BMC Cancer 2010, 10, 103
81. Pettit, G. R.; Rhodes, M. R. Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug Anti-Cancer Drug Des. 1998, 13, 183-191 (Pubitemid 28188203)
82. Bionomics. BNC105. http://www.bionomics.com.au/page.php?section=103.
83. Hamel, E.; Lin, C. M. Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization Biochemistry 1984, 23, 4173-4184
84. Hamel, E. Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin Cell Biochem. Biophys. 2003, 38, 1-22
85. Verdier-Pinard, P.; Lai, J.-Y.; Yoo, H.-D.; Yu, J.; Márquez, B.; Nagle, D. G.; Nambu, M.; White, J. D.; Falck, J. R.; Gerwick, W. H.; Day, B. W.; Hamel, E. Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells Mol. Pharmacol. 1998, 53, 62-76 (Pubitemid 28068373)